BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 2720661)

  • 21. A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo.
    Yamauchi T; Ueda T; Nakamura T
    Cancer Res; 1996 Apr; 56(8):1800-4. PubMed ID: 8620496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.
    Roberts D; Peck C; Hilliard S; Wingo W
    Cancer Res; 1979 Oct; 39(10):4048-54. PubMed ID: 476642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
    Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
    Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
    Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
    Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
    Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
    Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
    Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
    J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
    Damon LE; Plunkett W; Linker CA
    Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.
    Negoro E; Yamauchi T; Urasaki Y; Nishi R; Hori H; Ueda T
    Int J Oncol; 2011 Apr; 38(4):911-9. PubMed ID: 21290089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
    Gandhi V; Plunkett W
    Cancer Res; 1988 Jan; 48(2):329-34. PubMed ID: 3335008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arabinosyl-5-azacytosine: mechanisms of native and acquired resistance.
    Ahluwalia GS; Cohen MB; Kang GJ; Arnold ST; McMahon JB; Dalal M; Wilson YA; Cooney DA; Balzarini J; Johns DG
    Cancer Res; 1986 Sep; 46(9):4479-85. PubMed ID: 2425954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
    Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
    Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of thymidine on the sensitivity of cultured mouse tumor cells to 1-beta-D-arabinofuranosylcytosine.
    Harris AW; Reynolds EC; Finch LR
    Cancer Res; 1979 Feb; 39(2 Pt 1):538-41. PubMed ID: 761229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V; Xu YZ; Estey E
    Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux.
    Chan TC
    Cancer Res; 1989 May; 49(10):2656-60. PubMed ID: 2713849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
    Grant S; Turner AJ; Bartimole TM; Nelms PA; Joe VC; Jarvis WD
    Oncol Res; 1994; 6(2):87-99. PubMed ID: 7949469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
    Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.